Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer
NCT05172245Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2022
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ipatasertib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Maximum tolerated dose and recommended phase 2 dose up to 56 days. Started Sep 2022; status: recruiting.
02
Drugs
ipatasertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05172245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172245.